about
Lipid nanocapsules loaded with rhenium-188 reduce tumor progression in a rat hepatocellular carcinoma model(188)Re-SSS/Lipiodol: Development of a Potential Treatment for HCC from Bench to Bedside.68Ga and 188Re Starch-Based Microparticles as Theranostic Tool for the Hepatocellular Carcinoma: Radiolabeling and Preliminary In Vivo Rat Studies188Re-loaded lipid nanocapsules as a promising radiopharmaceutical carrier for internal radiotherapy of malignant gliomasMain applications of hybrid PET-MRI contrast agents: a review.Gemcitabine and Oxaliplatin, but Not Sorafenib or Paclitaxel, Have a Synergistic Effect with Yttrium-90 in Reducing Hepatocellular Carcinoma and Cholangiocarcinoma Cell Line Viability.In vitro demonstration of synergy/additivity between (188)rhenium and sorafenib on hepatoma lines: preliminary results.Tumor eradication in rat glioma and bypass of immunosuppressive barriers using internal radiation with (188)Re-lipid nanocapsules.Increased Lipiodol uptake in hepatocellular carcinoma possibly due to increased membrane fluidity by dexamethasone and tamoxifen.Occupational radiation exposure of medical staff performing ⁹⁰Y-loaded microsphere radioembolization.Development of Biocompatible and Functional Polymeric Nanoparticles for Site-Specific Delivery of Radionuclides.Chelated hydrazido(3-)rhenium(V) complexes: on the way to the nitrido-M(V) core (M = Tc, Re).Locoregional Confinement and Major Clinical Benefit of 188Re-Loaded CXCR4-Targeted Nanocarriers in an Orthotopic Human to Mouse Model of Glioblastoma.Syntheses and reactivity of 'sulfur rich' Re(iii) and Tc(iii) complexes containing trithioperoxybenzoate, dithiobenzoate and dithiocarbamate ligands.Stable and Inert Yttrium(III) Complexes with Pyclen-Based Ligands Bearing Pendant Picolinate Arms: Toward New Pharmaceuticals for β-Radiotherapy.Characterization of the distribution, retention, and efficacy of internal radiation of 188Re-lipid nanocapsules in an immunocompromised human glioblastoma model.Pyclen Tri-n-butylphosphonate Ester as Potential Chelator for Targeted Radiotherapy: From Yttrium(III) Complexation to (90)Y Radiolabeling.18th European Symposium on Radiopharmacy and RadiopharmaceuticalsThe role of the capping bond effect on pyclen natY3+/90Y3+ chelates: full control of the regiospecific N-functionalization makes the differenceMixed-ligand complexes of yttrium-90 dialkyldithiocarbamates with 1,10-phenanthroline as a possible agent for therapy of hepatocellular carcinomaReduction of β-radiation exposure during preparation of 188Re-labelled Lipiodol for hepatocellular carcinoma treatmentAutomation of labelling of Lipiodol with high-activity generator-produced 188ReEffect of Stabilized Iodized Oil Emulsion on Experimentally Induced Hepatocellular Carcinoma in Rats188Re-SSS lipiodol: radiolabelling and biodistribution following injection into the hepatic artery of rats bearing hepatomaDevelopment of 99mTc labelled Lipiodol: biodistribution following injection into the hepatic artery of the healthy pigTransarterial Radioembolization (TARE) Agents beyond Y-MicrospheresStudy of Binding Kinetics and Specificity of 99mTc-SSS-Complex and 99mTc-HMPAO to Blood Cells.Rhenium-188 Labeled Radiopharmaceuticals: Current Clinical Applications in Oncology and Promising Perspectives.Cell Uptake and Biocompatibility of Nanoparticles Prepared from Poly(benzyl malate) (Co)polymers Obtained through Chemical and Enzymatic Polymerization in Human HepaRG Cells and Primary Macrophages.Preliminary results of the Phase 1 Lip-Re I clinical trial: biodistribution and dosimetry assessments in hepatocellular carcinoma patients treated with 188Re-SSS Lipiodol radioembolization
P50
Q33847837-5F6EB3C8-940B-42C7-BBB6-01BE65B1C10DQ35821571-CDF92803-A2E4-4FEA-B907-6F0420B6B39EQ36163785-D21C9ED9-40F3-452B-AF01-F52268A1F041Q37331142-0CD97FB9-E77E-4B06-A3A8-28C29ACC435AQ38657496-4C302F2B-3C7D-4B01-93E6-2FDCEECCF1D3Q38817589-FB9E2EF3-6D79-45A3-9387-6301A30E1CD0Q39097437-8599D068-7008-46B7-BB53-0318CAED4777Q39517913-F53BD307-FB54-4EEF-81AF-4C0026BECF29Q39651597-043E3976-A1DF-43EF-9C2C-E8B79F162C3FQ40190325-C32A7E84-E359-4375-8469-7F646A391DD7Q42581457-D5DD9C04-D766-4D5E-8277-B334A05B4EEFQ43919245-506B34FA-3B5F-4BB7-A6BA-3B4113177425Q44243239-CF00AAC7-6215-4E36-9755-58009C6B7ED0Q46645094-E5857BB2-7B85-4261-8BE7-CE74E8576C09Q48106531-0D1F774A-B054-4E38-A7D4-DEB74D77E5F6Q48458408-A3C7BDDE-9667-459F-96EC-E31BD080C751Q52983466-2FA79D79-474B-457E-9D55-58890C9254B3Q57757530-D74EFD03-F0A3-4838-9E68-6FB8DC50C312Q58931428-DFD7EAA5-0F8E-4F53-A28F-3FA8571EFB8AQ58931467-BF8F7376-C9CD-49E6-94CF-04856487169BQ58931476-66D1B8A8-B20F-465A-9BBA-7E28A7293DC7Q58931481-C6FDB254-66B0-45DC-87C0-5B5AF8A3CA0FQ58931496-34687CBE-CFBF-4DD3-BB6A-E4D14C54469EQ58931502-FB9F0A59-8815-40B8-9B81-8ECBC9CA2C31Q58931512-4BB38A6E-46AC-44C9-A874-5A9F195A14E2Q61453275-0E075381-585F-4308-866F-F77CA864F67BQ64886038-4508B3F5-8DE9-4C88-B9A3-A7FD95223AAEQ64969976-96BA99B8-B284-4936-95F9-EC5BE64A0A3BQ64989776-F799B43A-D5DE-4D70-A522-7E2B6580772AQ91330479-FBABE3C9-0BDB-46D1-A49C-BA9EE6D73D75
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Nicolas Lepareur
@ast
Nicolas Lepareur
@en
Nicolas Lepareur
@es
Nicolas Lepareur
@nl
Nicolas Lepareur
@sl
type
label
Nicolas Lepareur
@ast
Nicolas Lepareur
@en
Nicolas Lepareur
@es
Nicolas Lepareur
@nl
Nicolas Lepareur
@sl
prefLabel
Nicolas Lepareur
@ast
Nicolas Lepareur
@en
Nicolas Lepareur
@es
Nicolas Lepareur
@nl
Nicolas Lepareur
@sl
P106
P1153
6506752107
P21
P31
P496
0000-0001-9860-5451